NMNashrah Mustafa

Nashrah Mustafa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nashrah Mustafa has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Applications and challenges of artificial intelligence in cancer management

    by Eva Rahman Kabir, Nashrah Mustafa, Zara Sheikh, Mehrin Haque Tanisha, Fariha Tasneem, Syeda Maliha Ahmed, Mashwiyat Samrin Roja, Adwiza Chakraborty Bishakha, Nishat Zareen Khair, Asef Raj

  • Open Access

    Beyond Weight Loss: Tirzepatide as a Metabolic Disease‐Modifying Strategy for Metabolic Dysfunction‐Associated Steatohepatitis: A Narrative Review

    by Zubaier Ahmed, Nashrah Mustafa, Tamanna Sarkar, Hasina Yasmin

    Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide and a major contributor to liver‐related morbidity and mortality. Its progressive subtype, metabolic dysfunction–associated steatohepatitis (MASH), is characterized by hepatocellular injury, inflammation, and fibrosis, which may ultimately progress to cirrhosis and hepatocellular carcinoma. Despite the rapidly increasing global burden of MASH, effective pharmacological therapies remain limited. Lifestyle modification remains the cornerstone of management; however, achieving and maintaining the degree of sustained weight loss required for meaningful histological improvement is challenging in routine clinical practice. Objective: This perspective review evaluates the emerging therapeutic potential of tirzepatide in the management of MASH. Methods: Relevant mechanistic studies, clinical trials, and recent literature published between 2015 and 2025 were reviewed to evaluate the emerging role of tirzepatide and incretin‐based therapies in metabolic liver disease. Results: Tirzepatide is a first‐in‐class dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist that produces substantial metabolic benefits, including improved glycemic control, enhanced insulin sensitivity, and significant weight reduction. These effects directly address key drivers of MASLD and MASH, including hepatic lipid accumulation, insulin resistance, and systemic inflammation. Emerging clinical evidence, particularly from the SYNERGY‐NASH trial, suggests that tirzepatide may promote resolution of steatohepatitis and improvement in fibrosis in patients with biopsy‐confirmed MASH. Conclusion: Tirzepatide represents a promising metabolic disease‐modifying therapy for MASH. Nevertheless, larger and longer‐term clinical studies are needed to establish its durability of benefit, long‐term safety, and optimal role within evolving treatment strategies for metabolic liver disease.

  • Open Access

    Translating Liquid Biopsy into Practice- The Promise and Challenges of Circulating Tumor Cells in Ovarian and Lung Cancer Management

    by Nashrah Mustafa, Mehrin Haque Tanisha, Fariha Tasneem, Ayman Siddique, Zubaier Ahmed, Namara Mariam Chowdhury, Fazle Rabbi

    The increasing mortality from ovarian and lung cancers worldwide is largely due to late diagnosis and therapeutic resistance. Conventional biomarkers such as CA125 and CYFRA 21-1 lack the sensitivity or the specificity for monitoring real time disease progression or therapeutic response. This has prompted researchers to work on the development of relevant biomarkers that are minimally invasive for cancer diagnosis, prognosis and for therapeutic stratification. As such, liquid biopsies, which analyze tumor-derived components circulating in the blood including circulating tumor cells (CTCs), which are shed from primary or metastatic tumors into the bloodstream have emerged as a promising approach for detecting such cancers. This review critically analyzes the diagnostic and prognostic significance of CTCs in ovarian and lung cancers, highlighting technological advances, molecular characterization, and translational challenges associated with their clinical application. It briefly discusses the clinical utility of some biomarkers from liquid biopsies used in the diagnosis, prognosis as well as monitoring of ovarian and lung cancers with their detection methods. It highlights some of the relevant studies conducted in the field and finally it provides insights on the future of liquid biopsies. An extensive literature review analyzing papers between 2008 and 2026 was conducted using PubMed, Scopus, and Web of Science databases, that evaluated CTC detection methods, molecular profiling, and clinical outcomes in ovarian and lung cancer patients. Current literature reports that CTC enumeration and molecular characterization can provide significant insights into disease progression, therapeutic resistance and predict survival outcomes. Whilst the enrichment technologies such as CellSearch ® , ISET, and microfluidic platforms have enhanced detection sensitivity, variability in assay performance and lack of a clinical standardization impede proper implementation. CTCs represent a powerful liquid biopsy tool with potential to revolutionize cancer diagnostics and precision medicine. Integration of multi-omics profiling, CTC-derived organoids, and AI-driven analytical models may further enhance their clinical utility in guiding personalized treatment strategies for ovarian and lung cancer patients.


  • Open Access

    Antioxidant, Anti‐inflammatory, Analgesic, and Antiarthritic Potentialities of Methanolic Extract of Fruit Husk of Nypa fruticans Wurmb, Established by In Silico Analysis

    by Farhana Alam Ripa, Ajoy Paul Adar, Adwiza Chakraborty Bishakha, Nashrah Mustafa, Mehrin Haque Tanisha, Nishat Zareen Khair, Zara Sheikh, Asef Raj, Israt Jahan Bulbul

    This study investigates the bioactive components and biological activities of the methanolic husk extract of Nypa fruticans Wurmb (MNF) through gas chromatography–mass spectrometry (GC‐MS) analysis. The MNF extract was identified to contain several bioactive components, including alkaloids, glycosides, phenols, tannins, and resins, as established through preliminary phytochemical screening tests. After finding the presence of antioxidant components in the qualitative antioxidative assay, we went to conduct quantitative tests where the total contents of phenolics, flavonoids, and tannins were estimated as 179.43 ± 3.99 mg GAE/g, 179.43 ± 3.99 mg QE/g, and 29.25 ± 0.29 mg TAE/g, respectively. The extract demonstrated notable antioxidant activity in DPPH free radical scavenging (IC 50 36.28 μ g/mL) and ferric reducing antioxidant power (83.27 % ± 0.02 % reduction) assays. The extract demonstrated notable in vitro anti‐inflammatory and antiarthritic properties in a dose‐dependent manner, as indicated by human red blood cell (HRBC) membrane stabilization (74.63 % ± 0.84 % at 5000 μ g/mL) and protein denaturation (88.77 % ± 0.31 % inhibition at 500 μ g/mL), relative to standards. The anti‐inflammatory efficacy of MNF extract was confirmed via an in vivo carrageenan‐induced inflammatory study, showing an 85.49% reduction in edema at the maximum dosage of 600 mg/kg. The extract demonstrated significant ( p < 0.05, p < 0.01, and p < 0.0001) and dose‐dependent analgesic effects in acetic acid–induced writhing and formalin‐induced pain assays. Molecular docking studies conducted with the selected compounds against potential targets identified 1‐(3,6,6‐trimethyl‐1,6,7,7a‐tetrahydrocyclopenta[c]pyran‐1‐yl) ethanone as the best candidate with promising analgesic and anti‐inflammatory potential, demonstrated by its high binding affinity comparable to or exceeding that of the selected standard drugs. Our findings indicate that N. fruticans fruit husk may serve as a viable source of natural chemicals possessing antioxidant, analgesic, anti‐inflammatory, and antiarthritic properties, demonstrating potential therapeutic effects in alleviating diseases associated with inflammatory responses.